Placebo for AMG 334
Sponsors
Amgen Inc.
Conditions
Chronic MigraineEpisodic Migraine
Phase 3
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to < 12 Years) and Adolescents (12 to < 18 Years) With Episodic Migraine (OASIS PEDIATRIC [EM])
RecruitingCTIS2023-504930-23-00
Start: 2019-07-19Target: 233Updated: 2025-10-16
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to < 12 Years) and Adolescents (12 to < 18 Years) With Chronic Migraine (OASIS PEDIATRIC [CM])
RecruitingCTIS2023-504928-26-00
Start: 2019-07-19Target: 101Updated: 2025-10-13